May 15, 2020 / 7:29 AM / 11 days ago

BRIEF-Diamyd Medical To Invest About SEK 3.2 Mln In Nextcell Pharma's Rights Issue

May 15 (Reuters) - Diamyd Medical AB:

* TO INVEST ABOUT SEK 3.2 MILLION IN NEXTCELL PHARMA’S RIGHTS ISSUE

* FOLLOWING DEAL CO’S INVESTMENT IN NEXTCELL PHARMA INCREASES FROM ABOUT SEK 8.5 MILLION TO ABOUT SEK 11.7 MILLION

* CO’S HOLDING IN NEXTCELL PHARMA IS 12.8% Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below